Lake Street initiated coverage on Beta Bionics with a new price target
$BBNX
Medical/Dental Instruments
Health Care
Lake Street initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2025 | Buy | BofA Securities | |
| 2/24/2025 | $30.00 | Buy | Lake Street |
| 2/24/2025 | $25.00 | Buy | Stifel |
| 2/24/2025 | $26.00 | Overweight | Piper Sandler |
| 2/24/2025 | $28.00 | Outperform | Leerink Partners |
| 2/20/2025 | $20.00 | Neutral | Ladenburg Thalmann |
| 2/20/2025 | $20.00 | Neutral | Robert W. Baird |
4 - Beta Bionics, Inc. (0001674632) (Issuer)
3 - Beta Bionics, Inc. (0001674632) (Issuer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
BofA Securities initiated coverage of Beta Bionics with a rating of Buy
Lake Street initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00
Stifel initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $25.00
IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c
IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived
IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its annual guidance for the year ending December 31, 2025. First Quarter 2025 Financial Results & Key Metrics Net sales of $17.6 million, up 36% compared to $12.9 million in the first quarter of 2024. Durable Medical Equipment (DME) channel net sales of $13.8 million, up 14% compared to $12.1 million in the first quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $3.8 million, up 360% compared to $0.8 million in the first quarte
IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at 12:35 pm Eastern Time (9:35 am Pacific Time). A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay following the event. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the desig
IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a
4 - Beta Bionics, Inc. (0001674632) (Issuer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
10-Q - Beta Bionics, Inc. (0001674632) (Filer)
8-K - Beta Bionics, Inc. (0001674632) (Filer)
10-K/A - Beta Bionics, Inc. (0001674632) (Filer)